ANIXA BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Other
ANIXA BIOSCIENCES, INC. (ANIX) reported Adjustments to Additional Paid in Capital, Other of $46.22 thousand for the 3-month period ending 2019-01-31, per its 10-Q filed 2019-03-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2019-03-13
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2019-01-31 was $46.22K, a 12.04% decline year-over-year.
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2018-10-31 was $121.10K.
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2018-07-31 was $70.89K.
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for the quarter ending 2018-04-30 was $73.61K.
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for fiscal 2018 was $318.14K, a 9528.90% increase from fiscal 2017.
- ANIXA BIOSCIENCES, INC. adjustments to additional paid in capital, other for fiscal 2017 was $3.30K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2019-01-31 | $46.22K 10-Q · filed 2019-03-13 | $167.32K derived: sum of 2 quarters · filed 2019-03-13 | $238.21K derived: sum of 3 quarters · filed 2019-03-13 | $311.81K derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-10-31 | $121.10K derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $191.99K derived: sum of 2 quarters · filed 2019-01-11 | $265.59K derived: sum of 3 quarters · filed 2019-01-11 | $318.14K 10-K · filed 2019-01-11 |
| 2018-07-31 | $70.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-09-07 | $144.49K derived: sum of 2 quarters · filed 2018-09-07 | $197.04K 10-Q · filed 2018-09-07 | |
| 2018-04-30 | $73.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-06-11 | $126.15K 10-Q · filed 2018-06-11 | ||
| 2018-01-31 | $52.55K 10-Q · filed 2018-03-09 | |||
| 2017-10-31 | $3.30K 10-K · filed 2019-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |